IBRX - Lifshitz Law PLLC Announces Investigations of ImmunityBio Inc. (NASDAQ: IBRX) BioXcel Therapeutics Inc. (NASDAQ: BTAI) Baxter International Inc. (NYSE: BAX) | Benzinga

NEW YORK, Sept. 30, 2023 (GLOBE NEWSWIRE) --

ImmunityBio, Inc. (NASDAQ:IBRX)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose that: (i) ImmunityBio conducted insufficient due diligence to discover, or else did discover and ignored, GMP deficiencies at its third-party CMOs for Anktiva; (ii) one or more of the Company's third-party CMOs for Anktiva did in fact suffer from GMP deficiencies; (iii) the foregoing deficiencies was likely to cause the FDA to reject the Anktiva BLA in its present form; (iv) accordingly, the Company overstated the regulatory approval prospects for the Anktiva BLA; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

If you are an IBRX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516) 493-9780 or e-mail at info@lifshitzlaw.com.

BioXcel Therapeutics, ...

IBRX), BioXcel Therapeutics, Inc. (NASDAQ: BTAI), Baxter International Inc. (NYSE: BAX)>Full story available on Benzinga.com